DNMT3B, DNA methyltransferase 3 beta, 1789

N. diseases: 315; N. variants: 38
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.040 Biomarker phenotype BEFREE miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma. 30718452 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.040 AlteredExpression phenotype BEFREE The dose-dependent upregulation of endogenous FOXM1 (isoform B) expression during tumour progression across a panel of normal primary NOK strains (n = 8), dysplasias (n = 5) and head and neck squamous cell carcinoma (HNSCC) cell lines (n = 11) correlated positively with endogenous expressions of HELLS, BMI1, DNMT1 and DNMT3B and negatively with p16(INK4A) and involucrin. 22461910 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.040 AlteredExpression phenotype BEFREE We found that Ment was gradually demethylated and overexpressed during tumor progression in Dnmt3b-/- lymphomas. 22133874 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.040 AlteredExpression phenotype BEFREE Linear mixed-effects modelling was used in this study to understand the onset and patterns of the methylation changes of SFRP2, IGF2 DMR0, H19, LINE-1 and a CpG island methylator phenotype (CIMP) marker panel, and they were correlated with DNA methyltransferase 3B (DNMT3B) levels of expression in a sample set representative of colorectal neoplastic progression. 21068132 2011